Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HERES Trial: Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients

NCT05170256 is registered in ClinicalTrials.gov with Morten Mau-Sørensen as lead sponsor.

NCT NCT05170256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05170256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HERES Trial: Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients
Lead sponsor
Morten Mau-Sørensen
Phase
Phase 2
Overall status
Unknown status
Start date
February 4, 2022
Completion date
January 31, 2025
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinoma, her-2 gene amplification, her-2 protein overexpression